Vertex Pharmaceuticals Files 8-K on Financials
Ticker: VRTX · Form: 8-K · Filed: May 6, 2024 · CIK: 875320
Sentiment: neutral
Topics: financial-reporting, 8-K, operations
Related Tickers: VRTX
TL;DR
VERTEX files 8-K with financial updates. Check it out.
AI Summary
Vertex Pharmaceuticals Incorporated filed an 8-K on May 6, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located at 50 Northern Avenue, Boston, Massachusetts.
Why It Matters
This filing provides crucial updates on Vertex Pharmaceuticals' financial performance and operational status, which can influence investor decisions and market perception.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not indicate any immediate or significant risks.
Key Players & Entities
- Vertex Pharmaceuticals Incorporated (company) — Registrant
- 50 Northern Avenue, Boston, Massachusetts 02210 (location) — Principal executive offices
- May 6, 2024 (date) — Date of report
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Vertex Pharmaceuticals Incorporated's results of operations and financial condition, including financial statements and exhibits.
When was this 8-K filing submitted?
This 8-K filing was submitted on May 6, 2024.
Where are Vertex Pharmaceuticals' principal executive offices located?
Vertex Pharmaceuticals' principal executive offices are located at 50 Northern Avenue, Boston, Massachusetts 02210.
What is the company's state of incorporation?
The company's state of incorporation is Massachusetts.
What is the Standard Industrial Classification code for Vertex Pharmaceuticals?
The Standard Industrial Classification code for Vertex Pharmaceuticals is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 516 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-05-06 16:03:09
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 Par Value Per Share VRTX The Nasdaq G
Filing Documents
- vrtx-20240506.htm (8-K) — 25KB
- ex-991_q12024.htm (EX-99.1) — 187KB
- 0000875320-24-000137.txt ( ) — 358KB
- vrtx-20240506.xsd (EX-101.SCH) — 2KB
- vrtx-20240506_lab.xml (EX-101.LAB) — 21KB
- vrtx-20240506_pre.xml (EX-101.PRE) — 12KB
- vrtx-20240506_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On May 6, 2024, we issued a press release in which we reported our consolidated financial results for the three months ended March 31, 2024. A copy of that press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. The information set forth in Exhibit 99.1 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Description of Document 99.1 Press Release Dated May 6 , 2024. 104 Cover Page Interactive Data File — the cover page XBRL tags are embedded within the Inline XBRL document.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VERTEX PHARMACEUTICALS INCORPORATED (Registrant) Date: May 6, 2024 /s/ Jonathan Biller Jonathan Biller Executive Vice President, Chief Legal Officer